Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Mechanism/class and chemical description claims are supported by the provided label excerpts, but several other claims are unsupported (not found in provided adverse reactions) and several indication/efficacy statements cannot be verified because the label’s Indications/Usage section was not provided.
Category Scores
Accurate Statements
Fesoterodine fumarate belongs to the class of medicines known as antimuscarinics (anticholinergics).
Supported partially: 11 (Description) and 12.1 describe fesoterodine as a muscarinic receptor antagonist/competitive muscarinic receptor antagonist.
Fesoterodine fumarate works by blocking muscarinic receptors involved in bladder muscle contractions.
12.1 (Mechanism of Action): “competitive muscarinic receptor antagonist” and “inhibition of these receptors in the bladder… presumed to be the mechanism…”
Fesoterodine fumarate refers to the drug fesoterodine in a specific salt form (fumarate).
11 (Description): “Toviaz contains fesoterodine fumarate.”
Unsupported Statements
Fesoterodine fumarate is a prescription medicine used to treat overactive bladder (OAB).
Indications and Usage (Section 1) text is not provided, so treatment of OAB cannot be confirmed from the supplied excerpts.
Fesoterodine fumarate helps reduce symptoms of overactive bladder such as urinary urgency and frequency.
Indications/clinical efficacy details are not provided (Section 1 not supplied).
Fesoterodine fumarate can reduce episodes of urge incontinence in adults with overactive bladder.
Indications/efficacy details are not provided (Section 1 not supplied).
Blocking muscarinic receptors involved in bladder muscle contractions can reduce involuntary bladder activity.
12.1 supports a presumed mechanism of inhibition of bladder muscarinic receptors but “involuntary bladder activity” is not explicitly stated in the provided excerpts.
Common side effects of antimuscarinic medicines like fesoterodine fumarate include dry mouth.
Provided Section 6 excerpt only lists angioedema, urinary retention, and decreased GI motility elsewhere; “dry mouth” is not included in the supplied excerpts.
Common side effects of antimuscarinic medicines like fesoterodine fumarate include constipation.
No “constipation” adverse reaction is included in the supplied Section 6 excerpt; only “Decreased Gastrointestinal Motility” is referenced.
Common side effects of antimuscarinic medicines like fesoterodine fumarate include blurred vision.
No blurred vision adverse reaction is included in the supplied label excerpts.
Common side effects of antimuscarinic medicines like fesoterodine fumarate include dizziness.
No dizziness adverse reaction is included in the supplied label excerpts.
Patients with existing bowel conditions or urinary retention often need extra caution with this drug class.
Contraindications list urinary retention and gastric retention, but the generalized “existing bowel conditions” / “often need extra caution” wording is not explicitly supported by the provided excerpt.
Patients with certain eye problems often need extra caution with this drug class.
The label excerpt provides a contraindication for uncontrolled narrow-angle glaucoma, but the generalized “certain eye problems” / “often need extra caution” language is not explicitly present.
In practice, the fumarate salt form is used to stabilize and deliver the active medicine.
The provided label excerpts describe that Toviaz contains fesoterodine fumarate and that fesoterodine is hydrolyzed to an active metabolite, but do not state that the fumarate salt form is used to “stabilize and deliver” the active medicine.
Contradictions
Important Omissions
Boxed warnings, detailed warnings/precautions, contraindications completeness (beyond the excerpt), dosage/administration instructions, drug interactions, and use in specific populations could not be fully assessed because those label sections (beyond the limited contraindications/warnings/adverse-reaction excerpts provided) were not included in the input.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported/overgeneralized adverse effect statements (e.g., “common side effects” including dry mouth/constipation/blurred vision/dizziness) and unverified efficacy/indication claims increase the risk of inaccurate label-alignment; however, mechanism/class and contraindication-relevant cautions were at least partially consistent with provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several claims (OAB treatment/efficacy and multiple “common side effects”) are not supported by the provided label excerpts; adverse reaction and efficacy content require the missing Label Section 1 and complete Section 6 adverse reaction lists.
Suggested Improvement
Remove or rephrase unsupported “common side effects” to only those adverse reactions explicitly listed in the provided label; cite Label Section 1 for OAB/urgency/frequency/urge incontinence claims; align caution statements to explicit contraindications (e.g., urinary retention; uncontrolled narrow-angle glaucoma) rather than generalized language.